Linearis

The impact SPANS the ENTIRE health continuum

Prevention

Fast
Accurate
Affordable

Early Diagnostics

Predictive response

Patient Monitoring

Personalized treatment

Drug Discovery

AI-Feedback loop for curative treatments

Linearis with its tandem Ventures Fund and Laboratory, is pioneering and supporting discoveries to prevent, detect, and cure diseases through direct investments in innovative AI-powered life sciences companies.

Linearis Labs

Provides the most comprehensive AI-driven metabolomics diseases signatures

Zilia

Non-Invasive Assessment of Biomarkers in the Eye. 510(k) & Health Canada approval


Feldan

Initiation Ph1/2b in basal cell carcinoma


Noetik

$50M USD AI-drug discovery licensing with GSK